Miracor Launches Next-Generation PICSO Impulse System in Europe

July 22, 2014—Miracor Medical Systems announced the launch of its next-generation PICSO Impulse system for the treatment of myocardial infarction. The new PICSO (pressure-controlled intermittent coronary sinus occlusion) system has European CE Mark approval and has been used to treat patients in the United Kingdom, Ireland, and Hungary.

The next-generation device consists of the Impulse console and Impulse balloon catheters. The system features a new, smaller balloon catheter that addresses variable patient anatomies as well as physician preferences and provides improved handling and increased balloon stability during PICSO therapy to treat ST-segment elevation myocardial infarction (STEMI) and non-STEMI patients as a complement to percutaneous coronary intervention (PCI). The system’s console and software have also been updated to facilitate faster, safe, and effective therapy delivery.

According to the company, the PICSO system is designed to increase myocardial perfusion in conjunction with primary PCI and thereby reduce infarct size and improve cardiac function. To date, approximately 160 patients have been treated, and the most recent clinical trial data presented at EuroPCR 2014 confirmed the safety and effectiveness of the Miracor PICSO technology to reduce infarct size in patients who had received PICSO therapy after PCI compared to a control group, the company stated.